banner

Investors

At Acadia, we remain deeply committed to providing important new therapies to patients and delivering value for our stockholders. Our Investor Center is designed to provide you with convenient access to company information.

Recent News

07/21/21
- Pimavanserin met the primary endpoint of reduced risk of relapse of psychosis by 2.8 fold   compared to placebo - Pimavanserin met the secondary endpoint of significantly reducing trial discontinuation for any reason by 2.2 fold SAN DIEGO --(BUSINESS WIRE)--Jul.
07/21/21
Company to host conference call and webcast on Wednesday, August 4, 2021 , at 4:30 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Jul. 21, 2021-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021 , after
07/14/21
SAN DIEGO --(BUSINESS WIRE)--Jul. 14, 2021-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that three scientific presentations in dementia-related psychosis (DRP) will be shared at the Alzheimer’s Association International Conference ® 2021 (AAIC ® ), being held July 26-30, 2021 in